CA2294549A1 - Piperidines a substitution heterocyclique et utilisations de ces dernieres - Google Patents
Piperidines a substitution heterocyclique et utilisations de ces dernieres Download PDFInfo
- Publication number
- CA2294549A1 CA2294549A1 CA002294549A CA2294549A CA2294549A1 CA 2294549 A1 CA2294549 A1 CA 2294549A1 CA 002294549 A CA002294549 A CA 002294549A CA 2294549 A CA2294549 A CA 2294549A CA 2294549 A1 CA2294549 A1 CA 2294549A1
- Authority
- CA
- Canada
- Prior art keywords
- branched
- straight chained
- alkyl
- compound
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cette invention concerne des composés d'oxazolidinone qui sont des antagonistes sélectifs des récepteurs .alpha.¿1A? humains. Cette invention concerne également les différentes utilisations de ces composés pour réduire la pression intra-oculaire, empêcher la synthèse du cholestérol, détendre les tissues du tractus urinaire inférieur, traiter l'hyperplasie prostatique bénigne, l'impuissance, l'arythmie cardiaque et pour traiter toute maladie dans laquelle l'antagoniste du récepteur .alpha.¿1A? peut être utile. Cette invention concerne également une composition pharmaceutique contenant une quantité thérapeutiquement efficace des composés présentés ci-avant ainsi qu'un support pharmaceutiquement acceptable.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87784697A | 1997-06-18 | 1997-06-18 | |
US08/877,846 | 1997-06-18 | ||
PCT/US1998/012668 WO1998057940A1 (fr) | 1997-06-18 | 1998-06-17 | Piperidines a substitution heterocyclique et utilisations de ces dernieres |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2294549A1 true CA2294549A1 (fr) | 1998-12-23 |
Family
ID=25370847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002294549A Abandoned CA2294549A1 (fr) | 1997-06-18 | 1998-06-17 | Piperidines a substitution heterocyclique et utilisations de ces dernieres |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0988295A4 (fr) |
JP (1) | JP2002505683A (fr) |
AU (1) | AU740064B2 (fr) |
CA (1) | CA2294549A1 (fr) |
WO (1) | WO1998057940A1 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6319932B1 (en) | 1998-11-10 | 2001-11-20 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1A adrenoceptor antagonists |
US6228870B1 (en) | 1998-11-10 | 2001-05-08 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1a adrenoceptor antagonists |
US6046331A (en) * | 1998-12-17 | 2000-04-04 | Synaptic Pharmaceutical Corporation | Imidazolones and their use in treating benign prostatic hyperplasia and other disorders |
GB2344821A (en) | 1998-12-17 | 2000-06-21 | Merck & Co Inc | Crystalline pharmaceutically acceptable salt of an oxazolidinone derivative |
US6372911B1 (en) * | 1999-02-09 | 2002-04-16 | Merck & Co., Inc. | Process for preparing β-hydroxycarbamates and their conversion to oxazolidinones |
US6645968B2 (en) | 1999-08-03 | 2003-11-11 | Abbott Laboratories | Potassium channel openers |
GB2355264A (en) | 1999-09-30 | 2001-04-18 | Merck & Co Inc | Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355263A (en) | 1999-09-30 | 2001-04-18 | Merck & Co Inc | Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355456A (en) | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355457A (en) | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists |
CA2678577A1 (fr) | 2007-02-26 | 2008-09-04 | Vitae Pharmaceuticals, Inc. | Inhibiteurs d'uree et de carbamate de 11b-hydroxysteroide deshydrogenase 1 cycliques |
AR069207A1 (es) | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
EP2229368A1 (fr) | 2007-12-11 | 2010-09-22 | Vitae Pharmaceuticals, Inc. | Inhibiteurs cycliques d'urée de la 11béta-hydroxystéroïde déhydrogénase 1 |
EP2324017B1 (fr) | 2008-07-25 | 2014-12-31 | Boehringer Ingelheim International GmbH | INHIBITEURS DE LA 11 bêta-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE 1 |
CA2730499A1 (fr) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Inhibiteurs cycliques de la 11 beta-hydroxysteroide deshydrogenase 1 |
CA2744946A1 (fr) | 2009-02-04 | 2010-08-12 | Boehringer Ingelheim International Gmbh | Inhibiteurs cycliques de la 11.beta.-hydroxysteroide deshydrogenase de type 1 |
UA109255C2 (ru) | 2009-04-30 | 2015-08-10 | Берінгер Інгельхайм Інтернешнл Гмбх | Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1 |
WO2011011123A1 (fr) | 2009-06-11 | 2011-01-27 | Vitae Pharmaceuticals, Inc. | Inhibiteurs cycliques de la 11-bêta-hydroxystéroïde déshydrogénase 1 basée sur la structure 1,3-oxazinan-2-one |
WO2011002910A1 (fr) | 2009-07-01 | 2011-01-06 | Vitae Pharmaceuticals, Inc. | Inhibiteurs cycliques de la 11-bêta-hydroxystéroïde déshydrogénase 1 |
EP2582698B1 (fr) | 2010-06-16 | 2016-09-14 | Vitae Pharmaceuticals, Inc. | Hétérocycles à 5, 6 et 7 chaînons substitués, médicaments contenant ces composés et leur utilisation |
JP5813106B2 (ja) | 2010-06-25 | 2015-11-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝障害の処置のための11−β−HSD1のインヒビターとしてのアザスピロヘキサノン |
EP2635268A1 (fr) | 2010-11-02 | 2013-09-11 | Boehringer Ingelheim International GmbH | Combinaisons pharmaceutiques destinées au traitement de troubles du métabolisme |
ES2734268T3 (es) | 2012-10-11 | 2019-12-05 | Southern Res Inst | Derivados de urea y amida de aminoalquilpiperazinas y uso de los mismos |
SG11202105250TA (en) * | 2018-11-20 | 2021-06-29 | Sironax Ltd | Cyclic Ureas |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3334098A (en) * | 1964-05-07 | 1967-08-01 | American Cyanamid Co | 1-monocarbocyclic aryl-3-amino-alkanoyl-2-imidazolidinones |
CH613205A5 (fr) * | 1975-06-06 | 1979-09-14 | Hoffmann La Roche | |
US4377578A (en) * | 1976-12-21 | 1983-03-22 | Janssen Pharmaceutica, N.V. | Piperazine derivatives |
US4410540A (en) * | 1981-11-04 | 1983-10-18 | Merrell Dow Pharmaceuticals Inc. | Cardiotonic 4-aroylimidazolidin-2-ones |
JPH0713017B2 (ja) * | 1986-06-18 | 1995-02-15 | 日本ケミファ株式会社 | 脳細胞保護作用を有する医薬組成物 |
JPH0755937B2 (ja) * | 1986-07-29 | 1995-06-14 | 日本曹達株式会社 | オキサ(チア)ゾリジン誘導体その製造方法及び殺ダニ剤 |
US5202345A (en) * | 1987-08-19 | 1993-04-13 | Shionogi & Co., Ltd. | Carbamoylpyrrolidone derivatives and drugs for senile dementia |
FR2698359B1 (fr) * | 1992-11-25 | 1995-10-27 | Rhone Poulenc Agrochimie | Derives de 2-alkoxy 2-imidazoline-5-ones fongicides. |
WO1995007904A1 (fr) * | 1993-09-15 | 1995-03-23 | Merck Sharp & Dohme Limited | Derives d'imidazolone et d'oxazolone utilises comme antagonistes de la dopamine |
NZ297278A (en) * | 1994-11-16 | 1999-06-29 | Synaptic Pharma Corp | 4-aryl dihydropyrimidine derivatives end medicaments |
WO1997017969A1 (fr) * | 1995-11-16 | 1997-05-22 | Synaptic Pharmaceutical Corporation | Dihydropirimidines et leurs emplois |
-
1998
- 1998-06-17 JP JP50477899A patent/JP2002505683A/ja active Pending
- 1998-06-17 WO PCT/US1998/012668 patent/WO1998057940A1/fr not_active Application Discontinuation
- 1998-06-17 EP EP98931350A patent/EP0988295A4/fr not_active Withdrawn
- 1998-06-17 AU AU81498/98A patent/AU740064B2/en not_active Ceased
- 1998-06-17 CA CA002294549A patent/CA2294549A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0988295A4 (fr) | 2003-08-13 |
AU740064B2 (en) | 2001-10-25 |
WO1998057940A1 (fr) | 1998-12-23 |
AU8149898A (en) | 1999-01-04 |
EP0988295A1 (fr) | 2000-03-29 |
JP2002505683A (ja) | 2002-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6620815B1 (en) | Oxazolidinones and uses thereof | |
CA2294549A1 (fr) | Piperidines a substitution heterocyclique et utilisations de ces dernieres | |
US6248747B1 (en) | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines | |
US6245773B1 (en) | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines | |
Moltzen et al. | Bioisosteres of arecoline: 1, 2, 3, 6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1, 2, 3-triazoles. Synthesis and muscarinic activity | |
CA2253862A1 (fr) | Dihydropyrimidines et leurs emplois | |
JP2021525219A (ja) | がんに対する使用のための、egfrの分解を引き起こす化合物 | |
JPH09501439A (ja) | ニューロキニンアンタゴニストとして有用な複素環 | |
CZ293134B6 (cs) | Substituované heterocyklické sloučeniny, způsob jejich přípravy, meziprodukty tohoto způsobu a farmaceutický prostředek obsahující tyto sloučeniny | |
CA2416667A1 (fr) | Sulfonamides cyclylamine en tant qu'agonistes du recepteur adrenergique beta-3 | |
US20050148583A1 (en) | Phenoxyalkylamine derivatives useful as opioid delta receptor ligands | |
US6727257B1 (en) | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines | |
US6531471B2 (en) | Morpholinone and morpholine derivatives and uses thereof | |
JP3545341B2 (ja) | Fkbp阻害剤 | |
AU769186C (en) | Imidazolones and their use in treating benign prostatic hyperplasia and other disorders | |
US6274585B1 (en) | Dihydropyrimidines and uses thereof | |
US6680323B2 (en) | Dihydropyrimidines and uses thereof | |
CA2355848A1 (fr) | Dihydropyrimidines et leurs utilisations | |
WO2000025782A1 (fr) | Dihydropyridinones et pyrrolinones utilisees comme antagonistes de l'adrenocepteur alpha 1a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |